I
Ixazomib
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Medical Assistance Fund
Active ingredient: Ixazomib
General information
Subsidy Information and Financing Scheme
[MAF] Ixazomib Capsule 3 mg, 4 mg
Ixazomib in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma who have received at least one prior therapy.
[MSHL] Ixazomib Capsule 3 mg, 4 mg
Ixazomib in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma who have received at least one prior therapy.
Drug Guidance for Subsidy
01/11/2025 Review of cancer drugs for previously treated multiple myeloma
The Ministry of Health’s Drug Advisory Committee has recommended:
Carfilzomib 30 mg powder for solution for infusion;
Ixazomib 3 mg and 4 mg capsules; and
Pomalidomide 1 mg, 2 mg, 3 mg and 4 mg capsules
for previously treated multiple myeloma in line with specific clinical criteria.
Carfilzomib, ixazomib and pomalidomide should be used in line with the recommended treatment regimens listed in the Annex.
Subsidy status
[R] Carfilzomib 30 mg powder for solution for infusion, ixazomib 3 mg and 4 mg capsules and pomalidomide 1 mg, 2 mg, 3 mg and 4 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) in line with the abovementioned indication.
[R] MAF assistance for carfilzomib will be implemented from 4 January 2022. MAF assistance for ixazomib and pomalidomide will be implemented from 1 September 2022.
[NR] MAF assistance does not apply to daratumumab 100 mg/5 ml and 400 mg/20 ml concentrate for solution for infusion and 1800 mg/15 ml solution for subcutaneous injection when used for previously treated multiple myeloma.
Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Capsule 3 mg |
|
Capsule 4 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.